Himachal Pradesh Government Orders Recall of 47 Substandard Medicines

In a significant move, the Himachal Pradesh government has ordered the recall of 47 medicines that failed quality tests. This decision follows a nationwide examination that identified numerous substandard drugs, with a notable number produced in Himachal Pradesh. The affected medications include those used for treating common ailments such as fever and diabetes. State officials have issued notices to the pharmaceutical companies involved, emphasizing the importance of maintaining quality standards. The Health Minister has warned that companies with repeated failures may face severe penalties, including blacklisting. This recall raises concerns about drug safety and quality in the region, prompting further scrutiny of pharmaceutical practices.
 | 
Himachal Pradesh Government Orders Recall of 47 Substandard Medicines

Recall of Medicines in Himachal Pradesh


The government of Himachal Pradesh has mandated pharmaceutical companies to withdraw 47 medications from circulation after quality tests revealed they did not meet standards.


State Drug Controller Manish Kapoor confirmed that notices have been sent to the relevant companies, requesting justifications and instructing them to remove the affected products from the market.


These failed samples were part of a broader examination of drugs conducted across the country, where a total of 200 samples were identified as substandard.


Among the 47 medicines produced in Himachal Pradesh are those prescribed for conditions such as fever, heart issues, diabetes, epilepsy, and muscle spasms.


Notable medications that did not pass the quality checks include paracetamol, clopidogrel, aspirin, metformin, ramipril, sodium valproate, and mebeverine hydrochloride.


Of the substandard samples, 28 were traced back to Solan district, 18 from Sirmaur, and one from Una, according to unnamed officials.


State Health Minister Dhani Ram Shandil previously indicated that companies with repeated quality failures would face blacklisting.